IgG-subclass-specific CMV reactivity in bone marrow transplant recipients

Area of Science:

• Immunology
• Transplantation Medicine
• Virology

Background:

• Cytomegalovirus (CMV) infections pose significant risks in immunocompromised individuals, particularly bone marrow transplant (BMT) recipients.
• Understanding the specific antibody responses, including IgG subclasses, is crucial for monitoring immune reconstitution and predicting outcomes post-BMT.

Purpose of the Study:

• To investigate the IgG subclass profiles of cytomegalovirus (CMV) antiviral antibodies in bone marrow transplant (BMT) recipients.
• To correlate CMV IgG subclass production with transplant take and clinical outcomes of CMV infection.

Main Methods:

• Analysis of IgG subclasses (IgG1 and IgG3) of CMV-specific antibodies in 37 donor-recipient pairs undergoing BMT.
• Measurement of passively transfused antibody subclasses.
• Detection of CMV in blood and urine samples.

Main Results:

• BMT recipients, similar to healthy individuals, predominantly produce CMV-specific IgG1 and IgG3 subclasses.
• Successful engraftment was indicated by the production of antiviral IgG subclasses 1-3 months post-BMT in seronegative recipients from seropositive donors.
• Patients with severe CMV infections showed decreasing IgG subclass titers, with CMV isolated from blood and urine, while those with moderate infections and recovery exhibited a strong, durable IgG subclass response with CMV primarily in urine.

Conclusions:

• CMV IgG subclass antibody production is a key indicator of immune recovery and successful engraftment after BMT.
• The pattern and durability of CMV IgG subclass responses differentiate between moderate and severe CMV infections in BMT recipients.